
Zimvie (ZIMV) Stock Forecast & Price Target
Zimvie (ZIMV) Analyst Ratings
Bulls say
ZimVie Inc has demonstrated resilience in a challenging implant market by increasing its market share, which bodes well for future revenue stability. The company's adjustment EBITDA margin improvement to 13.8%, reflecting a year-over-year increase of 250 basis points and surpassing consensus estimates, indicates strong operational efficiency. Additionally, the growth of domestic dental revenue, which outperformed expectations, reinforces the potential for sustained revenue growth in both the dental and spine segments in the coming years.
Bears say
ZimVie Inc. has reported a decline in organic revenue by 0.4% to $117 million, with domestic growth negatively impacted by lower iTero and implant sales, and a projected drop in revenue of 3-4% year-over-year for 3Q24. The company's operating margin decreased to 4.2%, falling 170 basis points year-over-year and significantly below consensus expectations of 7.7%, indicating potential challenges in operational efficiency. Furthermore, lowered earnings per share estimates for 2024 and 2025, combined with depressed dental multiples and declining revenue forecasts, suggest ongoing headwinds that could hamper ZimVie's financial performance.
This aggregate rating is based on analysts' research of Zimvie and is not a guaranteed prediction by Public.com or investment advice.
Zimvie (ZIMV) Analyst Forecast & Price Prediction
Start investing in Zimvie (ZIMV)
Order type
Buy in
Order amount
Est. shares
0 shares